Future is certain for niraparib in recurrent ovarian cancer
Announcement that niraparib from second line of treatment for recurrent ovarian cancer will be available long term on the NHS in England and Wales.
Read our latest updates from research breakthroughs to government actions to fundraising heroes.
Announcement that niraparib from second line of treatment for recurrent ovarian cancer will be available long term on the NHS in England and Wales.
New data reveals how aware the UK is of ovarian cancer and its symptoms.
Our new report confirms ovarian cancer has the second longest treatment wait times of all cancers.
Annwen Jones OBE, Chief Executive of Target Ovarian Cancer, becomes Chair of the World Ovarian Cancer Coalition.
Our first ever digital conference Moving Forwards Together was just the beginning...
New combination of olaparib and bevacizumab means a leap forward in personalised treatments.
Initial decision announced to make niraparib available from second line of treatment only to people with a BRCA1 or BRCA2 mutation.
Your donations will be matched pound for pound, up to £30,000!
We’re ending the postcode lottery in early diagnosis of ovarian cancer.
We welcome NHS England's landmark announcement to fund an ovarian cancer audit.
Our volunteers have been spreading the word, sharing stories and campaigning to raise awareness for Target Ovarian Cancer.
Research into screening for women with no symptoms of ovarian cancer concludes programme would not save lives.
Sign up to receive emails and keep up to date on all things Target Ovarian Cancer
Sign up